Health Canada Approves KALYDECO™ (ivacaftor), The First Medicine To Treat The Underlying Cause Of Cystic Fibrosis In People With A Specific Genetic Mutation (G551D)
Vertex Pharmaceuticals Incorporated (Nasdaq: VRTX) announced today that
Health Canada has approved KALYDECO
TM (ivacaftor), the first
medicine to treat the underlying cause of cystic fibrosis (CF), for
people ages 6...